The efficacy of combined treatment with MEK-inhibitor including dabrafenib/trametinib, was approved in melanoma [73] and NSCLC [74]; the combination of vemurafenib/cobimetinib and encorafenib/binimetanib only in melanoma [73,75,76]. This evidence concerns the gene MAP2K7 and melanoma.